ImpediMed Limited is an Australian medical technology company specializing in the development, manufacturing, and global distribution of noninvasive devices based on bioimpedance spectroscopy (BIS) technology. The company’s products, such as the SOZO Digital Health Platform, provide critical data for clinical assessment of conditions including lymphedema and heart failure by monitoring fluid status and tissue composition. SOZO integrates BIS with a cloud-based platform, enhancing patient and clinician engagement through real-time data management. Additional offerings include specialized devices for research applications and veterinary use. ImpediMed’s solutions serve hospitals, clinics, and research organizations, advancing standards in chronic disease management and personalized healthcare. Since its founding in 1999, ImpediMed has positioned itself as an innovative force within the global medical devices sector, leveraging FDA, CE, and ARTG certification for its technologies. The company generates most of its revenue from North America and maintains a presence in both the United States and Australia, reflecting its broad market significance in the healthcare industry.